

해외 바이오의약품 임상 현황 (2020.01.14~2020.01.20)

한국바이오의약품협회, 2020.1.21.
출처: ClinicalTrials.gov

○ 미국 15건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04159805	A Study to Evaluate Safety, Tolerability, and Efficacy of TAK-079 in Participants With Generalized Myasthenia Gravis	Myasthenia Gravis	Drug: TAK-079 Drug: TAK-079 Placebo	Takeda	Phase 2
NCT04077099	REGN5093 in Patients With MET-Altered Advanced Non-Small Cell Lung Cancer	NSCLC	Drug: REGN5093	Regeneron Pharmaceuticals	Phase 1 Phase 2
NCT04230213	A Comparative Study Between PF-06410293 and Humira® in Combination With Methotrexate in Participants With Active Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: PF-06410293 Drug: adalimumab	Pfizer	Phase 3
NCT04153422	IVIg in the Treatment of Autoimmune Small Fiber Neuropathy With TS-HDS or FGFR-3 Antibodies	Small Fiber Neuropathy Autoimmune Small Fiber Neuropathy Inflammatory Polyneuropathy Immune-Mediated Neuropathy	Drug: Gammagard IVIG Drug: Placebo	Loyola University Takeda	Phase 2
NCT04108195	A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma	Multiple Myeloma	Drug: Daratumumab Drug: JNJ-64407564 Drug: JNJ-64007957	Janssen Research & Development, LLC	Phase 1
NCT04117958	Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 199 in Subjects With MUC17-Positive Gastric and Gastroesophageal Junction Cancer	Gastric and Gastroesophageal Junction Cancer	Drug: AMG 199	Amgen	Phase 1
NCT04223804	A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of ABBV-181 (Budigalimab) in Adult Participants With HIV-1	Human Immunodeficiency Virus (HIV) HIV Infection HIV-1	Drug: ABBV-181 Drug: Placebo	AbbVie	Phase 1
NCT04197687	TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery	Breast Adenocarcinoma Stage II Breast Cancer AJCC v6 and v7 Stage IIA Breast Cancer AJCC v6 and v7 Stage IIB Breast Cancer AJCC v6 and v7 Stage III Breast Cancer AJCC v7 Stage IIIA Breast Cancer AJCC v7 Stage IIIB Breast Cancer AJCC v7 Stage IIIC Breast Cancer AJCC v7	Biological: Pertuzumab Other: Placebo Administration Biological: Sargramostim Biological: Trastuzumab Biological: Trastuzumab Emtansine Biological: Vaccine Therapy	Mayo Clinic National Cancer Institute (NCI)	Phase 2
NCT04165070	Substudy 1: Efficacy and Safety Study of Pembrolizumab (MK-3475) Plus Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYNOTE-01A)	Carcinoma, Non-Small-Cell Lung	Biological: Pembrolizumab Drug: Carboplatin Drug: Paclitaxel Drug: Pemetrexed Biological: MK-7684	Merck Sharp & Dohme Corp.	Phase 2
NCT04165096	Substudy 3: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Participants With Advanced Non-small Cell Lung Cancer (NSCLC), Previously Treated With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Therapy (MK-3475-01C/KEYNOTE-01C)	Carcinoma, Non-Small-Cell Lung	Biological: Pembrolizumab Biological: MK-5890	Merck Sharp & Dohme Corp.	Phase 2
NCT04209114	A Study of Nivolumab Plus NKTR-214 vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That Has Invaded the Muscle Wall of the Bladder and Who Cannot Get Cisplatin, a Type of Medicine Given to Treat Bladder Cancer.	Bladder Cancer Bladder Tumor Muscle-Invasive Bladder Cancer	Biological: Nivolumab Biological: NKTR-214 Procedure: Radical cystectomy (RC)	Bristol-Myers Squibb Nektar Therapeutics	Phase 3
NCT04047810	Mesenchymal Stem Cells in the Treatment of Subjects With Advance Chronic Obstructive Pulmonary Disease (COPD)	Chronic Obstructive Pulmonary Disease	Biological: Mesenchymal Stem Cells	Mayo Clinic	Phase 1
NCT03271814	Brain Biomarker on Inflammation Response	Schizophrenia	Biological: LPS Other: Placebo	University of Maryland, Baltimore	Phase 1
NCT04093323	Polarized Dendritic Cell (aDC1) Vaccine, Interferon Alpha-2, Rintalolimid, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma	HLA-A2 Positive Cells Present Refractory Melanoma	Biological: Alpha-type-1 Polarized Dendritic Cells Drug: Celecoxib Drug: PD-1 Ligand Inhibitor Drug: PD1 Inhibitor Biological: Recombinant Interferon Alfa-2b Drug: Rintalolimid	Roswell Park Cancer Institute National Cancer Institute (NCI)	Phase 2
NCT03735589	Specialized Immune Cells (nCTLs) and a Vaccine (Alpha-type-1 Polarized Dendritic Cells) in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	Stage II Fallopian Tube Cancer AJCC v8 Stage II Ovarian Cancer AJCC v8 Stage II Primary Peritoneal Cancer AJCC v8 Stage IIA Fallopian Tube Cancer AJCC v8 Stage IIA Ovarian Cancer AJCC v8 Stage IIA Primary Peritoneal Cancer AJCC v8 Stage IIB Fallopian Tube Cancer AJCC v8 Stage IIB Ovarian Cancer AJCC v8 Stage IIB Primary Peritoneal Cancer AJCC v8 Stage III Fallopian Tube Cancer AJCC v8 Stage III Ovarian Cancer AJCC v8 Stage III Primary Peritoneal Cancer AJCC v8 Stage IIIA Fallopian Tube Cancer AJCC v8 Stage IIIA Ovarian Cancer AJCC v8 Stage IIIA Primary Peritoneal Cancer AJCC v8 Stage IIIA1 Fallopian Tube Cancer AJCC v8 Stage IIIA1 Ovarian Cancer AJCC v8 Stage IIIA2 Fallopian Tube Cancer AJCC v8 Stage IIIA2 Ovarian Cancer AJCC v8 Stage IIIB Fallopian Tube Cancer AJCC v8 Stage IIIB Ovarian Cancer AJCC v8 Stage IIIB Primary Peritoneal Cancer AJCC v8 Stage IIIC Fallopian Tube Cancer AJCC v8 Stage IIIC Ovarian Cancer AJCC v8 Stage IIIC Primary Peritoneal Cancer AJCC v8 Stage IV Fallopian Tube Cancer AJCC v8 Stage IV Ovarian Cancer AJCC v8 Stage IV Primary Peritoneal Cancer AJCC v8 Stage IVA Fallopian Tube Cancer AJCC v8 Stage IVA Ovarian Cancer AJCC v8 Stage IVA Primary Peritoneal Cancer AJCC v8 Stage IVB Fallopian Tube Cancer AJCC v8 Stage IVB Ovarian Cancer AJCC v8 Stage IVB Primary Peritoneal Cancer AJCC v8	Biological: Alpha-type-1 Polarized Dendritic Cells Biological: Autologous Natural Killer Cell-like CTLs	Roswell Park Cancer Institute National Cancer Institute (NCI)	Phase 1 Phase 2

해외 바이오의약품 임상 현황 (2020.01.14~2020.01.20)

한국바이오의약품협회, 2020.1.21.
출처: ClinicalTrials.gov

○ 영국 1건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04209114	A Study of Nivolumab Plus NKTR-214 vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That Has Invaded the Muscle Wall of the Bladder and Who Cannot Get Cisplatin, a Type of Medicine Given to Treat Bladder Cancer.	Bladder Cancer Bladder Tumor Muscle-Invasive Bladder Cancer	Biological: Nivolumab Biological: NKTR-214 Procedure: Radical cystectomy (RC)	Bristol-Myers Squibb Nektar Therapeutics	Phase 3

○ 프랑스 2건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT03548428	Stereotaxic Body Irradiation of Oligometastase in Sarcoma (Stereosarc)	Sarcoma Radiosurgery	Drug: Atezolizumab Radiation: SBRT	Centre Antoine Lacassagne Centre Hospitalier Universitaire de Caen Roche Pharma AG	Phase 2
NCT04209114	A Study of Nivolumab Plus NKTR-214 vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That Has Invaded the Muscle Wall of the Bladder and Who Cannot Get Cisplatin, a Type of Medicine Given to Treat Bladder Cancer.	Bladder Cancer Bladder Tumor Muscle-Invasive Bladder Cancer	Biological: Nivolumab Biological: NKTR-214 Procedure: Radical cystectomy (RC)	Bristol-Myers Squibb Nektar Therapeutics	Phase 3

○ 독일 2건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04230759	Radiochemotherapy +/- Durvalumab for Locally-advanced Anal Carcinoma. A Multicenter, Randomized, Phase II Trial of the German Anal Cancer Study Group	Anal Cancer Anal Carcinoma Anal Cancer Stage III Anal Cancer Stage II	Drug: Chemotherapy Radiation: Radiation Drug: PD-L1	Goethe University	Phase 2
NCT04209114	A Study of Nivolumab Plus NKTR-214 vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That Has Invaded the Muscle Wall of the Bladder and Who Cannot Get Cisplatin, a Type of Medicine Given to Treat Bladder Cancer.	Bladder Cancer Bladder Tumor Muscle-Invasive Bladder Cancer	Biological: Nivolumab Biological: NKTR-214 Procedure: Radical cystectomy (RC)	Bristol-Myers Squibb Nektar Therapeutics	Phase 3

○ 중국 6건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04058470	Toripalimab in Combination With R-CHOP for Elderly Patients With Untreated Diffused B Cell Lymphoma	Diffuse Large B Cell Lymphoma High-grade B-cell Lymphoma Follicular Lymphoma Grade IIb Transformed Lymphoma EBV-Positive DLBCL, Nos ALK-Positive Anaplastic Large Cell Lymphoma	Drug: Toripalimab Drug: R-CHOP Protocol	Huiqiang Huang Sun Yat-sen University	Phase 1 Phase 2
NCT04218565	Golimumab for the Treatment of Refractory Behcet's Uveitis	Behcet Syndrome Uveitis	Biological: Golimumab (GOL)	Wenjie Zheng Peking Union Medical College Hospital	Phase 2
NCT04211090	Camrelizumab With AC in Patients With Brain Metastases of Driven Gene-negative, NSCLC	Non-squamous Non-small-cell Lung Cancer Brain Metastases	Drug: Camrelizumab Drug: Pemetrexed Drug: Carboplatin	Sun Yat-sen University Jiangsu HengRui Medicine Co., Ltd.	Phase 2
NCT04070040	Camrelizumab for Patients With Recurrent Primary Central Nervous System Lymphoma (PCNSL)	Primary Central Nervous System Lymphoma	Drug: Camrelizumab	Beijing Sanbo Brain Hospital	Phase 2
NCT04233151	QL1203 In Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine Efficacy and Safety	Metastatic Colorectal Cancer	Drug: QL1203 Drug: Placebo Drug: mFOLFOX6 regimen	Qilu Pharmaceutical Co., Ltd.	Phase 3
NCT04194203	A Study of Bevacizumab, Carboplatin, and Paclitaxel or Pemetrexed With or Without Atezolizumab in Chemotherapy-Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (IMpower151)	Carcinoma, Non-Small-Cell Lung	Drug: Atezolizumab Drug: Placebo Drug: Bevacizumab Drug: Paclitaxel Drug: Pemetrexed Drug: Carboplatin	Hoffmann-La Roche	Phase 3